---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-019217"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2022-04-11T23:59:59+00:00"
generated_at: "2026-06-26T08:18:28.312315+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# MoonLake Immunotherapeutics (fka Helix Acquisition) closes business combination, lists on Nasdaq

## Summary
- Closed business combination Apr 5, 2022; Helix acquired MoonLake AG, renamed MoonLake Immunotherapeutics (MLTX).
- Issued 36.9M Class A shares and 15.8M Class C shares; PIPE investors subscribed 11.7M Class A shares at $10.00 each, grossing ~$116M.
- Existing MoonLake AG shareholders received 18.5M Class A and 15.8M Class C shares; lock-up periods of 6 to 12 months apply.
- Helix contributed $134.6M to MoonLake AG, including $15M loan repayment to Cormorant Asset Management.
- New equity incentive plan adopted; initial grants of 45,000 options per non-management director; indemnification agreements executed.

## SEC filing metadata
- accession: 0001213900-22-019217
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2022-04-11T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.01, 9.01, 3.02, 3.03, 5.01, 5.02, 5.03, 5.05, 5.06, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000121390022019217/0001213900-22-019217-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000121390022019217/ea158227-8k_moonlake.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-019217
- JSON: https://secwatch.observer/filing/0001213900-22-019217.json
- Plain text: https://secwatch.observer/filing/0001213900-22-019217.txt

## Key facts
- Executive change
  Will Lewis resigned as Director at MoonLake Immunotherapeutics.
  - Action: resigned
  - Role: Director
  source text: In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1821586/000121390022019217/0001213900-22-019217-index.htm
- Executive change
  John Schmid resigned as Director at MoonLake Immunotherapeutics.
  - Action: resigned
  - Role: Director
  source text: In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1821586/000121390022019217/0001213900-22-019217-index.htm
- Executive change
  Dr. Andrew J. Phillips resigned as Officer at MoonLake Immunotherapeutics.
  - Action: resigned
  - Role: Officer
  source text: In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1821586/000121390022019217/0001213900-22-019217-index.htm
- Executive change
  Dr. Nancy Chang resigned as Director at MoonLake Immunotherapeutics.
  - Action: resigned
  - Role: Director
  source text: In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1821586/000121390022019217/0001213900-22-019217-index.htm
- Executive change
  Bihua Chen resigned as Officer at MoonLake Immunotherapeutics.
  - Action: resigned
  - Role: Officer
  source text: In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1821586/000121390022019217/0001213900-22-019217-index.htm
- Executive change
  Bihua Chen resigned as Director at MoonLake Immunotherapeutics.
  - Action: resigned
  - Role: Director
  source text: In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1821586/000121390022019217/0001213900-22-019217-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.